By Fineline Cube 
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million during the second quarter of 2025 (Q2 2025), ending June 30, 2025. This significant sales milestone underscores the growing market acceptance of the innovative BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy.
Carvykti Background
Carvykti, jointly developed by Legend Biotech and Johnson & Johnson, received approval in the U.S. in February 2022 and in China in August 2024. The therapy has shown remarkable growth, with net sales of USD 500 million in 2023 and USD 963 million in 2024.
Market Performance
The continued growth in Carvykti sales highlights its success in treating relapsed or refractory multiple myeloma. The therapy has been well-received in both U.S. and Chinese markets, reflecting its clinical value and patient demand.-Fineline Info & Tech